Symptom Burden and Quality of Life among Women with HER2+ Metastatic Breast Cancer
Corresponding Author
Kathleen Lang PhD
Boston Health Economics, Inc., Waltham, MA
Address correspondence and reprint requests to: Kathleen Lang, Boston Health Economics, Inc., 20 Fox Road, Waltham, MA 02451, USA, or e-mail: [email protected]Search for more papers by this authorSara Hurvitz MD
UCLA David Geffen School of Medicine, Los Angeles, California
Search for more papers by this authorDeepa Lalla PhD
Genentech Inc., South San Francisco, California
Search for more papers by this authorVictoria Federico BA
Boston Health Economics, Inc., Waltham, MA
Search for more papers by this authorMelissa Brammer MD, MPH
Genentech Inc., South San Francisco, California
Search for more papers by this authorDebu Tripathy MD
USC Keck School of Medicine, Los Angeles, California
Search for more papers by this authorCorresponding Author
Kathleen Lang PhD
Boston Health Economics, Inc., Waltham, MA
Address correspondence and reprint requests to: Kathleen Lang, Boston Health Economics, Inc., 20 Fox Road, Waltham, MA 02451, USA, or e-mail: [email protected]Search for more papers by this authorSara Hurvitz MD
UCLA David Geffen School of Medicine, Los Angeles, California
Search for more papers by this authorDeepa Lalla PhD
Genentech Inc., South San Francisco, California
Search for more papers by this authorVictoria Federico BA
Boston Health Economics, Inc., Waltham, MA
Search for more papers by this authorMelissa Brammer MD, MPH
Genentech Inc., South San Francisco, California
Search for more papers by this authorDebu Tripathy MD
USC Keck School of Medicine, Los Angeles, California
Search for more papers by this author
References
- 1Lobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 2013; 141: 507–14.
- 2Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271–7.
- 3Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2009; 28: 92–8.
- 4Kenne-Sarenmalm E, Ohlen J, Jonsson T, Gaston-Johansson F. Coping with recurrent breast cancer: predictors of distressing symptoms and health-related quality of life. J Pain Symptom Manage 2007; 34: 24–39.
- 5Aranda S, Schofield P, Weih L, et al. Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. European Journal of Cancer Care 2005; 14: 211–22.
- 6Yang HC, Thornton LM, Shapiro CL, Anderson BL. Surviving recurrence: psychological and quality of life recovery. Cancer 2008; 112: 1178–87.
- 7Low CA, Stanton A. Activity disruption and depressive symptoms in women living with metastatic breast cancer. Health Psychol 2014; 34: 89–92.
- 8Turner J, Kelly B, Swanson C, Allison R, Wetzig N. Psychosocial impact of newly diagnosed advanced breast cancer. Psycho-Oncology 2005; 14: 396–407.
- 9Seah D, Lin N, Curley C, Winer EP, Partridge A. Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis. Cancer Res 2012; 72(24 Suppl): 534s. (# P6-08-03 SABCS).
- 10Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007; 16: 1073–81.
- 11Mayer M, Grober SE. Patient perspectives on symptom control. The Breast 2013; 22(Supplement 3): S26–7. (IN24, ABC2, Advanced Breast Cancer Second International Consensus Conference).
